Health Care Equipment & Services

Coloplast’s revised valuation shows a cautious outlook amid Danish healthcare shifts – learn how cost control, reimbursement changes, and product innovation impact its growth.

Fisher & Paykel Healthcare’s latest earnings show steady growth driven by high‑margin respiratory and anaesthesia products, robust pipeline, and tariff‑mitigation strategies.

Intuitive Surgical’s decade‑long rise: from $73 to nearly $400, a $143B market cap, high margins, R&D edge, and proven robotic‑surgery value that beats industry averages.

Quest Diagnostics’ decade‑long stock growth, AI‑powered diagnostics, and at‑home testing reveal how the lab services leader outpaces peers and drives shareholder value in today’s evolving health ecosystem.

Smith & Neph PLC’s decade‑long share price trend and £9.5bn valuation reveal a modest decline amid strong mid‑cap resilience and strategic focus on consolidation and efficiency.

German DAX dips yet healthcare stocks, led by Fresenius Medical Care, hold steady—showing resilience amid Europe’s market volatility.

Boston Scientific’s new 14 M incentive options boost capital while aligning staff, shareholders and patient outcomes, fueling R&D and value‑based reimbursement success.

Humm Group (ASX: HUM) ends Credit Corp acquisition talks, reaffirming independent growth strategy and strong global presence in commercial lending and payments.

Demant’s upgraded ratings and new hearing‑aid launch drive bullish outlook—Morgan Stanley, Danske Bank and DNB Carnegie see growth and a higher target price.

Fresenius Medical Care’s first share‑buyback tranche boosts equity, supports digital kidney‑care growth, and sustains strong margins in a tight reimbursement market.